RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Christopher Navara to Breast Neoplasms

This is a "connection" page, showing publications Christopher Navara has written about Breast Neoplasms.
Connection Strength

0.068
  1. Navara CS. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Curr Pharm Des. 2004; 10(15):1739-44.
    View in: PubMed
    Score: 0.027
  2. Navara CS, Benyumov A, Vassilev A, Narla RK, Ghosh P, Uckun FM. Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Anticancer Drugs. 2001 Apr; 12(4):369-76.
    View in: PubMed
    Score: 0.022
  3. Ghosh S, Zheng Y, Jun X, Narla RK, Mahajan S, Navara C, Mao C, Sudbeck EA, Uckun FM. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin Cancer Res. 1998 Nov; 4(11):2657-68.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support